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Background: To explore novel platinum-based anticancer agents that are distinct from the structure and
interaction mode of the traditional cisplatin by forming the bifunctional intrastrand 1,2 GpG adduct, the
monofunctional platinum + DNA adducts with extensive non-covalent interactions had been studied. It was
reported that the monofunctional testosterone-based platinum(II) agents present the high anticancer activity.
Moreover, it was also found that the testosterone-based platinum agents could cause the DNA helix to undergo
significant unwinding and bending over the non-testosterone-based platinum agents. However, the interaction
mechanisms of these platinum agents with DNA at the atomic level are not yet clear so far.
Results: In the present work, we used molecular dynamics (MD) simulations and DNA conformational dynamics
calculations to study the DNA distortion properties of the testosterone-based platinum + DNA, the improved
testosterone-based platinum + DNA and the non-testosterone-based platinum + DNA adducts. The results show
that the intercalative interaction of the improved flexible testosterone-based platinum agent with DNA molecule
could cause larger DNA conformational distortion than the groove-face interaction of the rigid testosterone-based
platinum agent with DNA molecule. Further investigations for the non-testosterone-based platinum agent reveal
the occurrence of insignificant change of DNA conformation due to the absence of testosterone ligand in such
agent. Based on the DNA dynamics analysis, the DNA base motions relating to DNA groove parameter changes
and hydrogen bond destruction of DNA base pairs were also discussed in this work.
Conclusions: The flexible linker in the improved testosterone-based platinum agent causes an intercalative
interaction with DNA in the improved testosterone-based platinum + DNA adduct, which is different from the
groove-face interaction caused by a rigid linker in the testosterone-based platinum agent. The present
investigations provide useful information of DNA conformation affected by a testosterone-based platinum complex
at the atomic level.
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Since the discovery of cisplatin [cis-(NH3)2PtCl2], as an
anticancer agent, a series of platinum anticancer drugs
were used in treatment of various cancers in clinical
chemotherapy [1-6]. The platinum(II) center of traditional
cisplatin reacts with DNA forming two covalent bonds to
N7 atoms of two adjacent guanine (G) bases with the bi-
functional intrastrand 1,2 GpG adduct, to prevent the
replication and transcription of cancer genes, and ultim-
ately to induce tumor cell apoptosis [6-9]. However, the
efficacy of traditional cisplatin is often compromised be-
cause of the intrinsic and acquired resistance, as well as
the toxic side effects [3,10-14]. Much effort has been
devoted to the developments of novel platinum-based
anticancer agents which might form monofunctional plat-
inum+DNA adducts with extensive non-covalent interac-
tions to circumvent such drawbacks [11,15,16]. The
structures of these monofunctional platinum+DNA ad-
ducts with extensive non-covalent interactions are different
from that produced by cisplatin [8,9]. To the best of our
knowledge, the non-covalent interactions in platinum+
DNA adducts, mostly resulting from the interactions be-
tween the ligands of platinum agents and DNA molecules,
include the electrostatic interaction, groove-face inter-
action and intercalative interaction [17-22]. Especially, the
groove-face and intercalative interactions could greatly
stabilize the distorted DNA molecule via hydrogen bonds
and hydrophobic interactions, etc [17,18,20,21]. Therefore,
some pioneering strategies toward improving the lig-
and properties of monofunctional platinum agents have
emerged [15,23-27]. However, the systematic studies on
the relationship between the ligand properties of platinum
agents and interaction modes in the platinum + DNA
adducts have not yet been clearly detailed so far.
Recently, it has been shown that the monofunctional
platinum complexes of nitrogen-containing heterocyclic
amines, such as pyridine, pyrimidine, purine, piperidine,
picoline, and their derivatives could enhance cytotox-
icity, perhaps because of formations of monofunctional
platinum +DNA adducts rather than those of bifunc-
tional ones [15,23]. Especially, Hannon and co-workers
reported that the linkage of a testosterone to aromat-
ic N-heteroatomic monofunctional platinum(II) agents
confers relatively high activity to otherwise non-active
platinum(II) agents. Moreover, they indicated that the
conjugation of testosterone enhances the delivery ability
into the tumor cell, and inherent antitumor activity of
testosterone-based platinum agents [26]. Importantly, it
was also proved that the testosterone-based platinum
agents cause the DNA helix to undergo significant un-
winding and bending over the non-testosterone-based
platinum agents. This might be caused by the steric bulk
of testosterone which requires greater unwinding/bend-
ing of DNA helix to accommodate the agent in theDNA double helix [27]. Theoretically, the structures of
some new designed drugs were usually optimized by the
density functional theory (DFT) method [28]. Some
molecular dynamics (MD) simulations were used for in-
vestigating the interaction properties between DNA mol-
ecule and different platinum agents, such as cisplatin,
oxaliplatin, [PtCl(en)(ACRAMTU-S)](NO3)2 and so on
[29-36]. Moreover, the MD simulations were also used
for investigating the molecular interactions between the
androgen receptor protein and testosterones in the plat-
inum agents [24,37]. However, few theoretical studies
devoted to the interactions between the monofunctional
N-heteroatomic platinum agents with the testosterone li-
gands and DNA molecules.
Delineating the structural details of DNA bound by plat-
inum agents will help us to understand the features that
are responsible for the remarkable potency of these plat-
inum agents. Nevertheless, how the testosterone ligands
affect the interaction modes of platinum agents with DNA
molecules is still unknown. In the present work, we used
molecular dynamics simulations and DNA dynamics ana-
lysis to study the conformational properties of DNA dis-
turbed by different monofunctional N-heteroatomic
platinum agents. Due to the potent antitumor activity
of cis-[Pt(Testo)Cl][NO3] ( Testo = (NH3)2(17α-pyridyl-3-
ethynyltestosterone)) as a rigid testosterone-based plat-
inum agent studied by Hannon and co-workers [26], the
first MD simulation was performed on the Pt(Testo)(II) +
DNA adduct to investigate interaction properties of this
platinum agent with DNA, and effects of the testosterone
ligand on DNA conformation. To better understand the
effects of the testosterone ligand on interaction modes in
the platinum+DNA adducts, the second MD simulation
was performed on the improved Pt(Testo)(II) agent with
flexible linker interacting with DNA molecule. To com-
pare with these two testosterone-based platinum agents, a
non-testosterone-based platinum agent adding to DNA
molecule has also been simulated.
Methods
Initial structures
On the basis of previous experimental studies [26,27], we
choose the initial structure of the cis-[ Pt(Testo)Cl][NO3]
( Testo = (NH3)2(17α-pyridyl-3-ethynyltestosterone)) from
the geometry optimized by the DFT method at the
B3LYP/6-31G** + LanL2DZ level of theory due to the in-
existence of its crystal structure (see Figure 1(a)). The cor-
responding geometry parameters with the available
experimental data from similar molecules are shown in
Additional file 1: Table S1 and Additional file 2: Figure S1.
The 20bp DNA fragment, 50-d(CGGTGAAAACCTC
TGACACA)-30, was chosen from the primer PUC19
F studied by the experiment of polymerase-chain reac-
tion (PCR) [27] and shown in Figure 1(b). To build a Pt
Figure 1 Calculated structures of the studied platinum agents and the DNA sequence. Calculated structures of the studied platinum
agents: (a) Pt(Testo)(II), (b) the 20bp DNA sequence ( The G15 base is the binding site to platinum center), (c) Im-Pt(Testo)(II), (d) Pt(Py)(II).
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our simulations were generated by manually docking
[38-40]. Namely, the platinum center is bound to the N7
atom of G15 base in the major groove of DNA due to the
experimental prediction for a similar platinum agent [25].
The plane of platinum center coordinated by four ligands
is perpendicular to the plane of G15 base; ultimately, the
linked pyridyl ring is approximately perpendicular to the
base pair planes of DNA, and is parallel to the wall of
major groove of DNA; the testosterone ligand with four
5/6-membered rings linked to the pyridyl ring is approxi-
mately localized around the T14:A27 base pair across the
major groove of DNA, minimising the steric overlap be-
tween the agent and the DNA molecule. Since several dif-
ferent orientations of platinum center plane to the G15
base of DNA for the Pt(Testo)(II) + DNA adduct were
chosen as the starting structures for our MD simulations,
this provides a good test of whether our MD simulations
are capable of driving significantly distinct starting struc-
tures to a non-distinguishable one when simulations reach
equilibrium. To further investigate the influence of testos-
terone ligand of platinum agent on interaction modes, we
improved the flexibility of linker between the pyridyl and
testosterone ligands in the Pt(Testo)(II) agent with chan-
ging the linker of ethynyl –C ≡C– to that of ethyl –CH2–
CH2– (assigned as Im-Pt(Testo)(II) agent); simultaneously
a non-testosterone-based platinum agent, cis-[ Pt (NH3)2
(pyridine)Cl][NO3] (assigned as Pt(Py)(II) agent), was also
chosen to perform a comparison. The Im-Pt(Testo)(II)
and Pt(Py)(II) agents were fully optimized by the same
method used for the Pt(Testo)(II) agent, and shown inFigure 1(c) and (d) [26,27]. The Im-Pt(Testo)(II) + DNA
and Pt(Py) (II) + DNA adducts were similarly built by
using the same method for the Pt(Testo)(II) + DNA ad-
duct described above. To compare the differences between
the DNA adduct conformations and an undamaged DNA
molecule, a bare-DNA (B-DNA) molecule simulation was
also performed, in which an idealized B-DNA with the
same base-pair sequence in these adducts was used as a
starting structure for the simulation. Given that each
strand of DNA has some phosphate groups, Na+ coun-
terions were added to each system to achieve elec-
troneutrality. The systems were explicitly solvated using
the TIP3P water potential inside a box large enough to en-
sure the solvent shell extended to 10 Å in all directions.
Force field parameter preparation
The atom types for the studied platinum agents, ex-
cept for the platinum atoms, were generated using the
ANTECHAMBER module in the AMBER9 program
[41]. The electrostatic potentials of the platinum agents
used for RESP charge calculations were calculated at the
B3LYP/6-31G** + LanL2DZ [28,31,42,43] level of theory
using the Gaussian09 program [44]. The RESP charges
of platinum agents were derived by the RESP program
based on the calculated electrostatic potentials. The
force field parameters around the Pt center were ge-
nerated by quantum chemical calculations, which was
reported particularly in our previous work [45,46]. Other
force field parameters of the platinum agents were
generated from the gaff force field in the AMBER9
program.
Figure 2 RMSD values of Pt(Testo)(II) + DNA, Im-Pt(Testo)(II) +
DNA, Pt(Py)(II) + DNA and B-DNA models. RMSD values of all
backbone atoms in the simulations of Pt(Testo)(II) + DNA (magenta),
Im-Pt(Testo)(II) + DNA (red), Pt(Py)(II) + DNA (black) and B-DNA (olive)
models with respect to the corresponding starting structure.
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All MD simulations were carried out using the AMBER9
package [41] with the parm99 force field [47,48], the
parmbsc0 refinement [49] and gaff [50] force field pa-
rameters. The details of MD protocols are given in
Additional file 3: Methodology.
Principal component analysis
Principal component analysis can be used to segre-
gate large-scale correlated motions from random ther-
mal fluctuations, thereby probing the essential dynamics
of the system. The details of this analysis method are
available in Additional file 3: Methodology.
DNA groove parameter analyses
The frequency distributions (fraction of the time spent
in each conformation) from the trajectories of simula-
tions for the models and a canonical B-DNA were calcu-
lated using the CURVES program [51] to investigate the
distortion of DNA. To account for the distortion of
whole DNA backbone, the overall bend, tilt and roll
angles of the DNA time-averaged structures for the
studied models were calculated by using the MadBend
program from the CURVES outputs [52]. The details of
the calculation method are available in Additional file 3:
Methodology.
Results
The root-mean-square deviation (RMSD) values of
all backbone atoms referenced to the corresponding
starting structures over all three trajectories for the
Pt(Testo)(II) + DNA, Im-Pt(Testo)(II) + DNA and Pt(Py)
(II) + DNA models were examined to determine if each
system had attained equilibrium. It is often considered
that small RMSD values of a simulation indicate a stable
state of the system. Plots of RMSDs of three system sim-
ulations over times are shown in Figure 2. It can be seen
from Figure 2 that each platinum +DNA adduct reached
equilibrium after 30 ns, and their energies were found
to be stable during the remainder of each simulation.
Therefore, the trajectory analysis for each of three sys-
tems has extracted the equilibrated conformation be-
tween 30 ns and 50 ns of simulation time, recording
10000 snapshots at every 2 ps time-interval of each
trajectory.
Disturbance of DNA conformation by the binding of Pt
(Testo)(II) agent via groove-face interaction
Conformation analysis of Pt(Testo)(II) + DNA adduct
Based on the results of previous experiment [27], the
testosterone-based platinum agent, cis-[Pt(NH3)2(17α-
pyridyl-3-ethynyltestosterone)Cl]+ (called Pt(Testo)(II)),
which consists of testosterone, ethynyl linker and plat-
inum(II) center coordinated by one chlorine atom andthree nitrogen atoms from two ammonias and one
pyridyl, as an efficient anticancer agent, binding to a
DNA molecule (called Pt(Testo)(II) + DNA adduct), was
tested by MD simulation. The average structure of Pt
(Testo)(II) + DNA adduct was obtained by the trajectory
analysis extracting the equilibrated conformations be-
tween 30 ns and 50 ns of simulation times and shown in
Figure 3 along with that of undamaged DNA molecule.
It is demonstrated from this average structure that the
testosterone with a groove-face interaction mode locates
at the major groove of DNA molecule; the platinum
center binds to the N7 atom of G15 base of DNA mol-
ecule; the pyridyl ring is perpendicular to the plane of
G15 base of DNA; the plane of testosterone with the
rigid ethynyl (–C ≡ C–) linker is perpendicular to the
pyridyl ring and plane of T14:A27 base pair of DNA
molecule.
Because the testosterone ligand locates at the DNA
major groove via the groove-face interaction mode, both
major groove and minor groove of DNA molecule tend
to widen and shoal. Figure 4 shows the DNA groove pa-
rameters around the connection sites, C11:G30 ~ G15:
C26 base pairs of DNA, which are near to the testoster-
one position, for the Pt(Testo)(II) + DNA and B-DNA
models. Namely, the average major groove width and
minor groove width increase from 12.13 to 13.68 Å and
from 5.75 to 8.04 Å, respectively, compared to a normal
B-DNA; then their depths are shoaled from 6.00 to 2.04 Å
and from 4.73 to 3.63 Å, respectively (Figure 4(a), (b), (c),
(d) and (e); see the red lines with circles and the black lines
with squares for the Pt(Testo)(II) + DNA and B-DNA
models, respectively). In addition, the measured degrees of
overall DNA bend, tilt and roll angles for the bound-DNA
backbone conformation of Pt(Testo)(II) + DNA adduct
Figure 3 The average centroid structures of three adducts with an undamaged B-DNA. The average centroid structures of three adducts :
(a) Pt(Testo)(II) + DNA, (b) Im-Pt(Testo)(II) + DNA and (c) Pt(Py)(II) + DNA (the double-strand DNA backbones (cyan) and the studied platinum
agents in stick (Pt: orange, N: blue, C: red, O: pink)) along with an undamaged B-DNA (light gray).
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deviation percentage of helical angles with respect to
the undamaged B-DNA molecule is 261.64% (260.02%
for bend; 270.54% for tilt; 254.37% for roll) for the
Pt(Testo)(II) + DNA adduct. Interestingly, the bend angle
toward the major groove was observed, which suggests
there is great stability of this adduct for this orientation
with the groove-face interaction mode. As expected, the
testosterone-based platinum agent could cause a great
DNA helical conformation distortion, which is consistent
with the previous experimental study [27].
Hydrogen bond and hydrophobic interaction analyses of
Pt(Testo)(II) + DNA adduct
To address the extent of DNA distortion through the
groove-face interaction mode, the destruction of hydro-
gen bonds in the DNA molecule and the formation of
new hydrogen bonds between the Pt agent and DNA
molecule have been analyzed and shown in Figure 5,
Figure 6(a) and Table 2, respectively. A distance of less
than 3.5 Å and an angle of greater than 120° between
the potential hydrogen bond donor and acceptor were
used as the criteria for a hydrogen bond formation
[33,53]. Due to the interaction of testosterone ligand
with DNA bases at the major groove, the hydrogenbonds at T14:A27 base pair in DNA molecule are com-
pletely destroyed compared with the undamaged B-DNA
(see Figure 5). The destructions of hydrogen bonds re-
sult from the formations of some new hydrogen bonds
between the C-H groups of testosterone ligand and O6
atom of G28 base, and between the C-H groups of
pyridyl ligand and O6 atom of G15 base with 20.82%
and 13.78% occupancy times, respectively (see Table 2
and Figure 6(a)). Moreover, hydrophobic interactions,
defined as a distance between carbon atoms shorter
than 4.5 Å, have been analyzed and shown in Table 3.
Namely, it was found that the hydrophobic interactions
between the carbon atoms of testosterone ligand and
carbon atoms of C26, A27 and T14 bases of DNA oc-
cur with the occupancy times of 211.69%, 36.08% and
23.44%, respectively. Both hydrogen bond destruction
in DNA molecule and new interaction formation of
Pt(Testo)(II)-DNA interface facilitate the DNA distor-
tion, which might make DNA repair more difficult.
Disturbance of DNA conformation by the binding of Im-Pt
(Testo)(II) agent via intercalative interaction
It has been shown from the structure analysis of Pt
(Testo)(II) + DNA adduct discussed above that the Pt
(Testo)(II) agent interacts with DNA molecule adopting
Figure 4 Groove widths and depths of B-DNA, Pt(Testo)(II) + DNA, Im-Pt(Testo)(II) + DNA and Pt(Py)(II) + DNA models. (a) The scheme of
the minor and major groove widths/depths for the time-average structures of DNA conformations for the Pt(Testo)(II) + DNA adduct and B-DNA.
(b) The major groove width; (c) the major groove depth; (d) the minor groove width; (e) the minor groove depth for the time-average structures
of DNA conformations for the Pt(Testo)(II) + DNA adduct (red lines with circles), Im-Pt(Testo)(II) + DNA adduct (Magenta lines with down-triangles),
Pt(Py)(II) + DNA adduct (blue lines with up-triangles) and B-DNA (black lines with square symbols) (black lines with squares).
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Table 1 Values of average overall bend, tilt and roll
angles (°) for the DNA conformations of the studied
adducts and undamaged B-DNA
Adducts Bend Tilt Roll
B-DNA 11.73 6.89 9.49
Pt(Testo)(II) + DNA 42.23 25.53 33.63
Im-Pt(Testo)(II) + DNA 47.46 45.03 14.96
Pt(Py)(II) + DNA 28.49 17.19 22.72
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nyl –C ≡C– linker between the testosterone and pyridyl
ligands. To produce great effects of Pt(Testo)(II) agent
on DNA conformation distortion via intercalative inter-
action mode, the rigid ethynyl –C ≡C– linker in the
Pt(Testo)(II) agent was changed to a flexible linker,
ethyl –CH2–CH2–, in order to build a new modified
platinum agent, called Im-Pt(Testo)(II). The Im-Pt
(Testo)(II) agent, as an improved anticancer agent, bind-
ing to a DNA molecule (called Im-Pt(Testo)(II) + DNA
adduct) was also tested by MD simulation. The average
structure of Im-Pt(Testo)(II) + DNA adduct are shown in
Figure 3 along with that of undamaged DNA molecule,
and demonstrates that the plane of testosterone ligand
embeds into the middle of T12 and C13 bases of DNA
molecule at the DNA major groove via an intercalative
interaction mode, and parallels to both T12 and C13
bases; the platinum center also binds to the N7 atom of
G15 base of DNA molecule; the pyridyl ring is still per-
pendicular to the plane of G15 base of DNA. The DNA
conformation distortion greatly increases due to the modi-
fied platinum agent interacting with DNA molecule via
the intercalative interaction mode.Figure 5 Hydrogen bond occupancies of base pairs along with
base-pair steps for three adducts. Hydrogen bond occupancies of
base pairs along with base-pair steps for each adduct: Pt(Testo)(II) +
DNA (black lines with squares); Im-Pt(Testo)(II) + DNA (Magenta lines
with down-triangles); Pt(Py)(II) + DNA (blue lines with up-triangles).Because the testosterone ligand embeds into the bases
of DNA molecule at the major groove via the intercalative
interaction mode, the major and minor grooves of DNA
molecule in the Im-Pt(Testo)(II) + DNA adduct become
wider and shallower than those in the Pt(Testo)(II) +
DNA adduct. Namely, the average width of DNA major
groove in the Im-Pt(Testo)(II) + DNA adduct increases by
74.27% (from 13.68 Å to 23.84 Å) compared to the Pt
(Testo)(II) + DNA adduct; then the average major groove
depth and minor groove depth are shoaled by 14.71%
(from 2.04 Å to 1.74 Å) and by 18.73% (from 3.63 Å to
2.95 Å), respectively (Figure 4(b), (c) and (e); see the red
lines with circles and the Magenta lines with down-triangles
for Pt(Testo)(II) +DNA and Im-Pt(Testo)(II) +DNA ad-
ducts, respectively). In addition, the average deviation per-
centage of helical angles for the Im-Pt(Testo)(II) +DNA
adduct is larger by 43.63% than that for the Pt(Testo)
(II) + DNA adduct (see Table 1). Similarly, the occupancy
percentages of formations of new hydrogen bonds and
hydrophobic interactions in the Im-Pt(Testo)(II) + DNA
adduct are larger than those in the Pt(Testo)(II) + DNA
adduct due to the intercalative interaction mode, except
for the same extent destruction of hydrogen bonds at the
T12:A29 base pair of DNA molecule compared with the
Pt(Testo)(II) + DNA adduct. Namely, the Im-Pt(Testo)
(II) + DNA adduct spends more occupancy times by
38.14% (from 34.60% to 72.74%) forming new hydro-
gen bonds between the C-H groups of testosterone ligand
and the O2/N3/N3 atom of T12/A29/G30 base than the
Pt(Testo)(II) + DNA adduct (shown in Figure 6(b)); simul-
taneously, it still spends more occupancy times by 178.5%
(from 271.21% to 449.71%) forming more hydrophobic in-
teractions between C atoms of testosterone and C atoms
of T12/C13/A29/G30 base, and between C atoms of ethyl
linker and C atoms of T14 base (shown in Table 3). These
results predict that the distortion of DNA conformation in
the Im-Pt(Testo)(II) + DNA adduct via the intercalative
interaction mode is greater than that in the Pt(Testo)
(II) + DNA adduct via the groove-face interaction
mode.
Binding of a non-testosterone-based platinum agent
to DNA
Based on the previous experiments [26,27], a non-
testosterone-based platinum complex displays little anti-
cancer activity. We also performed MD simulation on
the non-testosterone-based platinum agent, cis-[Pt(NH3)
2(pyridine)Cl]
+ (assigned as Pt(Py)(II)), in which a plat-
inum(II) center is coordinated by one chlorine atom and
three nitrogen atoms from two ammonias and only one
pyridine, binding to DNA molecule (assigned as Pt(Py)
(II) + DNA adduct). It can be found that there is hardly
any change in DNA conformation and DNA groove pa-
rameters in the Pt(Py)(II) + DNA adduct compared with
Figure 6 Hydrogen bonds between platinum ligands and DNA molecule. Hydrogen bonds between platinum ligands and DNA molecule:
(a) Pt(Testo)(II) + DNA and (b) Im-Pt(Testo)(II) + DNA (the DNA bases and the platinum complexes in tube, platinum atoms in orange, nitrogen
atoms in blue, oxygen atoms in Magenta, hydrogen atoms in white, carbon atoms of DNA molecule in cyan and carbon atoms of the complexes
in red).
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the blue lines with up-triangles and the black lines with
squares for the Pt(Py)(II) + DNA and B-DNA models, re-
spectively), except that the average deviation percentage
of helical angle is 143.93% with respect to the undam-
aged B-DNA molecule (see Table 1). Simultaneously,
there are no any destruction of hydrogen bond in the
DNA molecule and formation of new hydrogen bond/
hydrophobic interaction between the Pt(Py)(II) agent
and DNA molecule in the Pt(Py)(II) + DNA adduct due
to no testosterone ligand in the Pt(Py)(II) agent. These
results suggest that the DNA conformation changes
caused by the binding of the non-testosterone-based
platinum agent are unconspicuous, which predicts that
the non-testosterone-based Pt(Py)(II) agent is an ineffi-
cient anticancer agent reported by the previous experi-
ment [27].
Discussions
Principal component analysis of major conformational
dynamics
Principal component analysis was used to analyze the
trajectories from the corresponding simulations to exa-
mine the dominant DNA dynamic motions in the studied
Pt + DNA adducts. The first three principal componentsTable 2 Occupancies of hydrogen bonds between carbon hyd
near bases on DNA (electron donor)
Adducts Electron donor
Pt(Testo)(II) + DNA G28/O6
G15/O6
Im-Pt(Testo)(II) + DNA T12/O2
A29/N3
G30/N3(PC1, PC2 and PC3) described about 80% of all the mo-
tion modes of dynamics for Pt(Testo)(II) + DNA, Im-Pt
(Testo)(II) + DNA and Pt(Py)(II) + DNA adducts (see
Table 4). It was found that the first three components of
conformational motions roughly correspond to a super-
position of bending, unwinding and twisting motions (see
Additional file 4: Movie S1, Additional file 5: Movie S2
and Additional file 6: Movie S3, respectively, for the Im-
Pt(Testo)(II) + DNA adduct). The overall average centroid
structures of these adducts were analyzed and shown in
Figure 3. Visual analyses of average DNA structures from
the trajectories support the PCA dominant motions. It
can be seen that the DNA conformations of Pt + DNA
adducts with the groove-face and intercalative interaction
modes including the bending, unwinding and twisting
motions show obvious differences from the undamaged
B-DNA conformation. For example, the percentages of
occupancy times of PC1 and PC2 with the bending and
unwinding motions, respectively, for both the Pt(Testo)
(II) + DNA and Im-Pt(Testo)(II) + DNA adducts are lar-
ger than those for the Pt(Py)(II) + DNA adduct, which
predicts that the platinum agents with the big-size testos-
terone ligand binding to DNA molecule via either groove-
face interaction mode or intercalative interaction mode
lead to greater bending and unwinding for DNA doublerogen atoms of platinum agent (electron acceptor) and






Table 3 Occupancies of hydrophobic interactions
between carbon atoms of platinum agent and near bases
on DNA
Adducts Ligand DNA Occupancy (%)
Pt(Testo)(II) + DNA Ctestosterone C26 211.69
Ctestosterone A27 36.08
Ctestosterone T14 23.44
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the twisting motions for all three adducts make little con-
tribution to the distortion of DNA conformation.
DNA conformational dynamics in the Pt + DNA adducts
with different interaction modes
The Pt(Testo)(II) and Im-Pt(Testo)(II) agents respectively
via the groove-face and intercalative interaction modes
locate at the major groove of DNA and disturb the
DNA conformation greatly. The frequency distributions
of DNA helical dynamics parameters at the base pairs
near the binding site and testosterone position have been
analyzed and shown in Figure 7 and Additional file 7:
Figure S2 for the Pt(Testo)(II) + DNA and Im-Pt(Testo)
(II) + DNA adducts, respectively, along with the distribu-
tion patterns of the undamaged B-DNA. Generally, the
groove width and depth were measured mainly by the
opening, twist and rise motions, and the shift motion for
DNA bases, respectively, which has been defined by the
Curves analysis [54-56].
In the Pt(Testo)(II) + DNA model, the opening param-
eter of DNA base pair helix near the testosterone po-
sition T14:A27 base pair is changed by ~ -50° away from
the B-DNA molecule (see Figure 7); the deviations of
twist angle values are ~ -35º, ~25º, ~-25º and ~20º for
the C13 · T14, T14 · G15, C26 · A27 and A27 · G28 base
pair steps with respect to ~ 36º for a base pair step of
B-DNA molecule, in which the value of 25º is agreement
with the unwinding angle of 21º determined by using
gel mobility shift assays for the Pt(Testo)(II) agent inTable 4 Percentages of occupancy times of the first three
principal components during the simulations of the
studied Pt + DNA adducts
Adducts PC1 PC2 PC3 PCsa
Pt(Testo)(II) + DNA 68.48 20.39 4.95 93.82
Im-Pt(Testo)(II) + DNA 57.34 19.65 8.34 85.33
Pt(Py)(II) + DNA 44.31 22.42 13.88 80.61
a: PCs represents sum of PC1, PC2 and PC3.plasmid DNA solution [43]; moreover, the deviations of
rise values are ~ -1.5Å, ~5Å and ~4.5Å for the T12 · C13,
C13 · T14 and C26 · A27 base pair steps, respectively,
with respect to ~ 3.5 Å for the B-DNA molecule (see
Figure 7), which results in a widening of major groove
by 1.55 Å and minor groove by 2.29 Å around the C11:
G30 ~ G15:C26 base pairs (see Figure 4(a), (b) (red line)
and (d) (red line)). The deviations of shift values
are ~2Å, ~1.5Å, ~-2.5Å and ~ -2Å for the T12 · C13,
T14 · G15, C26 · A27and A27 · G28 base pair steps, re-
spectively, away from the B-DNA molecule (see Figure 7),
which results in a shoaling of major groove by 3.96 Å
and minor groove by 1.10 Å around the C11:G30 ~
G15:C26 base pairs (see Figure 4(a), (c) (red line) and
(e) (red line)). In addition, the deviations of roll angle
values are ~15°, ~-25º, ~40º and ~ -20° for the T12 ·
C13, C13 · T14, C26 · A27 and A27 · G28 base pair
steps, respectively, away from the B-DNA molecule
(see Figure 7), which contributes to the significant
bend of DNA helix toward the major groove by 30.50°.
Moreover, the conformational dynamics of DNA hel-
ical parameters in the vicinity of the testosterone pos-
ition are associated with the pattern of hydrogen bond
destruction and formation. For example, except of the
opening parameter mentioned above, the propel, stagger,
and stretch parameters for the DNA molecule in the Pt
(Testo)(II) + DNA model near the testosterone position
T14:A27 base pair are also changed by ~ -20°, ~4Å
and ~ -2.5Å, respectively, away from the B-DNA mol-
ecule, which results in the destruction of hydrogen
bonds at the base pair T14:A27. In addition, the DNA
base motions of shift, twist at T14 · G15 and A27 · G28
base pair steps, and roll at A27 · G28 base pair step with
the large deviations mentioned above (see Figure 7) are as-
sociated with the formations of new hydrogen bonds be-
tween the C-H groups of testosterone ligand and O6 atom
of G28 base, and between the C-H groups of pyridyl lig-
and and O6 atom of G15 base with 20.82% and 13.78% oc-
cupancy times, respectively, for the Pt(Testo)(II) + DNA
adduct (see Figure 6(a) and Table 2 ). These calculated re-
sults suggest that the DNA base dynamics motions caused
by DNA-bound testosterone-based platinum agents in-
duce DNA conformational distortion via the rearrange-
ment of hydrogen bonds at the vicinity of testosterone
position.
The deviation extents of DNA dynamics parameters
in the Im-Pt(Testo)(II) + DNA model away from the
B-DNA molecule are generally larger than those in the
Pt(Testo)(II) + DNA model. For example, the deviations
of twist angle values for the C26 · A27 base pair step in
the Im-Pt(Testo)(II) + DNA model increases by 80%
(from ~ -25º to ~ -45º) with respect to that in the Pt
(Testo)(II) + DNA model. Especially, the deviation direc-
tions of some DNA dynamics parameters in the Im-Pt
Figure 7 Frequency distributions of DNA duplex base-pair helical/step parameters for Pt(Testo)(II) + DNA adduct and B-DNA. Selected
frequency distributions of representative DNA duplex base-pair helical/step parameters at the base pairs near the binding site and testosterone
position for Pt(Testo)(II) + DNA adduct (red line) and B-DNA (black line).
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(Testo)(II) + DNA model. For example, the deviation dir-
ection of opening motion with ~65° at the T12:A29 base
pair in the Im-Pt(Testo)(II) + DNA model is opposite to
that with ~ -50° at the T14:A27 base pair in the Pt
(Testo)(II) + DNA model, which suggests the difference
of groove-face and intercalative interaction modes in the
platinum +DNA adducts. These observations result
from the intercalative interaction mode making the base
pair step opening to the DNA major groove by a positive
value, and oppositely the groove-face interaction mode
making that opening to the minor groove by a negative
value due to the testosterone ligand locating at the DNA
major groove surface. These observations suggest that
the different interaction modes of platinum agents with
DNA molecules caused by the flexibility of platinumagents might greatly affect the DNA base dynamics mo-
tions and DNA conformational damage. Moreover, it
can be seen in the present study that the intercalative
interaction mode of platinum agent with DNA molecule
might induce extensive DNA conformation distortion
over the groove-face interaction mode in the platinum
agent + DNA adducts.
Conclusions
Molecular dynamics simulations and DNA dynamics ana-
lyses for a series of the Pt + DNA adducts were carried
out to examine the distortions of DNA double-helical
structure perturbed by the binding of testosterone-based
platinum agent Pt(Testo)(II) (cis-[Pt(NH3)2(17α-pyridyl-3-
ethyltestosterone)](II)), improved testosterone-based pla-
tinum agent Im-Pt(Testo)(II) (cis-[Pt(NH3)2(17α-pyridyl-
Cui et al. BMC Structural Biology 2013, 13:4 Page 11 of 12
http://www.biomedcentral.com/1472-6807/13/43-ethynyltestosterone)](II)) and non-testosterone pla-
tinum agent Pt(Py)(II) (cis-[Pt(NH3)2(pyridine)](II)). It has
been found that the rigid testosterone-based platinum
agent Pt(Testo)(II) interacts with the DNA molecule via
the groove-face interaction mode at the major groove of
DNA; however, the improved flexible testosterone-based
platinum agent Im-Pt(Testo)(II) interacts with DNA mol-
ecule via the intercalative interaction mode with the tes-
tosterone ligand inserting the middle of T12 and C13
bases. The distortion of DNA helical conformation caused
by Im-Pt(Testo)(II) agent with intercalative interaction
mode is larger than that caused by the Pt(Testo)(II) agent
with groove-face interaction mode, which is supported by
the formations of more hydrogen bonds and hydrophobic
interactions at the platinum agent-DNA interface in the
Im-Pt(Testo)(II) + DNA adduct. It can be found through
the DNA dynamics analysis that the DNA base motions
of opening, shift, rise, roll and twist away from the DNA
groove caused by the binding of Pt(Testo)(II) and Im-Pt
(Testo)(II) agents result in the widening and shoaling of
DNA major/minor groove, and hydrogen bond destruc-
tion of DNA base pairs. Moreover, the non-testosterone
-based platinum agent Pt(Py)(II) might cause insignificant
change of DNA conformation due to the absence of tes-
tosterone ligand. Our simulation results might provide
useful insights into understanding how a DNA conform-
ation is affected by a testosterone-based platinum complex
at the atomic level, and might be helpful for anticancer
agent design.
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